This work is licensed under the Creative Commons Attribution 4.0 International License.
Campbell M, Castillo L, Riccheri C, Janic D, Jazbec J, Kaiserova E, et al. ALL ICBFM 2009. A randomized trial of the I-BFM-SG for the management of childhood non-B acute lymphoblastic leukemia. Final version of therapy protocol from August 14 2009. [Internet]. [cited 2023 Mar 15]. Available at https://www.bialaczka.org/wp-content/uploads/2016/10/ALLIC_BFM_2009.pdfCampbellMCastilloLRiccheriCJanicDJazbecJKaiserovaEALL ICBFM 2009A randomized trial of the I-BFM-SG for the management of childhood non-B acute lymphoblastic leukemia. Final version of therapy protocol from August 14 2009. [Internet][cited 2023 Mar 15]. Available at https://www.bialaczka.org/wp-content/uploads/2016/10/ALLIC_BFM_2009.pdfSearch in Google Scholar
Maury S, Chevret S, Thomas X, Heim D, Leguay T, Huguet F, et al. Rituximab in B-lineage adult acute lymphoblastic leukemia. N Engl J Med 2016; 375: 1044–53. doi: 10.1056/nejmoa1605085MaurySChevretSThomasXHeimDLeguayTHuguetFRituximab in B-lineage adult acute lymphoblastic leukemiaN Engl J Med201637510445310.1056/nejmoa1605085Open DOISearch in Google Scholar
Hayden PJ, Roddie C, Bader P, Basak, GW, Bonig H, Bonini C, et al. Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA). Ann Oncol 2022; 33: 259–75. doi: 10.1016/j.annonc.2021.12.003HaydenPJRoddieCBaderPBasakGWBonigHBoniniCManagement of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA)Ann Oncol2022332597510.1016/j.annonc.2021.12.003Open DOISearch in Google Scholar
Li Y, Moriyama T, Yoshimura S, Zhao X, Li Z, Yang X, et al. PAX5 epigenetically orchestrates CD58 transcription and modulates blinatumomab response in acute lymphoblastic leukemia. Sci Adv 2022; 8: eadd6403. doi: 10.1126/sciadv.add6403LiYMoriyamaTYoshimuraSZhaoXLiZYangXPAX5 epigenetically orchestrates CD58 transcription and modulates blinatumomab response in acute lymphoblastic leukemiaSci Adv20228eadd640310.1126/sciadv.add6403Open DOISearch in Google Scholar
Yan X, Chen D, Ma X, Wang Y, Guo Y, Wei J, et al. CD58 loss in tumor cells confers functional impairment of CAR T cells. Blood Adv 2022; 6: 5844–56. doi: 10.1182/bloodadvances.2022007891YanXChenDMaXWangYGuoYWeiJCD58 loss in tumor cells confers functional impairment of CAR T cellsBlood Adv2022658445610.1182/bloodadvances.2022007891Open DOISearch in Google Scholar
Hunger SP, Raetz EA. How I treat relapsed acute lymphoblastic leukemia in the pediatric population. Blood 2020; 136: 1803–12. doi: 10.1182/blood.2019004043HungerSPRaetzEAHow I treat relapsed acute lymphoblastic leukemia in the pediatric populationBlood202013618031210.1182/blood.2019004043Open DOISearch in Google Scholar
Dworzak MN, Schumich A, Printz D, Pötschger U, Husak Z, Attarbaschi A, et al. CD20 up-regulation in pediatric B-cell precursor acute lymphoblastic leukemia during induction treatment: setting the stage for anti-CD20 directed immunotherapy. Blood 2008; 112: 3982–88. doi: 10.1182/blood-2008-06-164129DworzakMNSchumichAPrintzDPötschgerUHusakZAttarbaschiACD20 up-regulation in pediatric B-cell precursor acute lymphoblastic leukemia during induction treatment: setting the stage for anti-CD20 directed immunotherapyBlood200811239828810.1182/blood-2008-06-164129Open DOISearch in Google Scholar
Gaipa G, Basso G, Maglia O, Leoni V, Faini A, Cazzaniga G, et al. Drug-induced immunophenotypic modulation in childhood ALL: implications for minimal residual disease detection. Leukemia 2005; 19: 49–56. doi: 10.1038/sj.leu.2403559GaipaGBassoGMagliaOLeoniVFainiACazzanigaGDrug-induced immunophenotypic modulation in childhood ALL: implications for minimal residual disease detectionLeukemia200519495610.1038/sj.leu.2403559Open DOISearch in Google Scholar
Gaipa G, Basso G, Aliprandi S, Migliavacca M, Vallinoto C, Maglia O, et al. Prednisone induces immunophenotypic modulation of CD10 and CD34 in nonapoptotic B-cell precursor acute lymphoblastic leukemia cells. Cytometry B Clin Cytom 2008; 74: 150–5. doi: 10.1002/cyto.b.20408GaipaGBassoGAliprandiSMigliavaccaMVallinotoCMagliaOPrednisone induces immunophenotypic modulation of CD10 and CD34 in nonapoptotic B-cell precursor acute lymphoblastic leukemia cellsCytometry B Clin Cytom200874150510.1002/cyto.b.20408Open DOISearch in Google Scholar
van der Sluijs-Gelling AJ, van der Velden VHJ, Roeffen ETJM, Veerman AJP, van Wering ER. Immunophenotypic modulation in childhood precursor-BALL can be mimicked in vitro and is related to the induction of cell death. Leukemia 2005; 19: 1845–7. doi: 10.1038/sj.leu.2403911van der Sluijs-GellingAJvan der VeldenVHJRoeffenETJMVeermanAJPvan WeringERImmunophenotypic modulation in childhood precursor-BALL can be mimicked in vitro and is related to the induction of cell deathLeukemia2005191845710.1038/sj.leu.2403911Open DOISearch in Google Scholar
Chen D, Gerasimčik N, Camponeschi A, Tan Y, Wu Q, Brynjolfsson S, et al. CD27 expression and its association with clinical outcome in children and adults with pro-B acute lymphoblastic leukemia. Blood Cancer J 2017; 7: e575. doi: 10.1038/bcj.2017.55ChenDGerasimčikNCamponeschiATanYWuQBrynjolfssonSCD27 expression and its association with clinical outcome in children and adults with pro-B acute lymphoblastic leukemiaBlood Cancer J20177e57510.1038/bcj.2017.55Open DOISearch in Google Scholar
Riether C, Schürch CM, Bührer ED, Hinterbrandner M, Huguenin AL, Hoepner S, et al. CD70/CD27 signaling promotes blast stemness and is a viable therapeutic target in acute myeloid leukemia. J Exp Med 2017; 214: 359–80. doi: 10.1084/jem.20152008RietherCSchürchCMBührerEDHinterbrandnerMHugueninALHoepnerSCD70/CD27 signaling promotes blast stemness and is a viable therapeutic target in acute myeloid leukemiaJ Exp Med20172143598010.1084/jem.20152008Open DOISearch in Google Scholar
Starzer AM, Berghoff AS. New emerging targets in cancer immunotherapy: CD27 (TNFRSF7). ESMO Open 2020; 4(Suppl 3): e000629. doi: 10.1136/esmoopen-2019-000629StarzerAMBerghoffASNew emerging targets in cancer immunotherapy: CD27 (TNFRSF7)ESMO Open20204Suppl 3e00062910.1136/esmoopen-2019-000629Open DOISearch in Google Scholar
Aljurf M, Chaudhri NA, Almhareb F, Walter CU, Nounou R, Khalil S, et al. CD34 expression in adult acute lymphoblastic leukemia (ALL) Is a favorable prognostic factor in patients treated with stem cell transplant in first remission. Blood 2011; 118: 4091. doi: 10.1182/blood.v118.21.4091.4091AljurfMChaudhriNAAlmharebFWalterCUNounouRKhalilSCD34 expression in adult acute lymphoblastic leukemia (ALL) Is a favorable prognostic factor in patients treated with stem cell transplant in first remissionBlood2011118409110.1182/blood.v118.21.4091.4091Open DOISearch in Google Scholar
Dakka N, Bellaoui H, Bouzid N, Khattab M, Bakri Y, Benjouad A. CD10 and CD34 expression in childhood acute lymphoblastic leukemia in morocco: clinical relevance and outcome. Pediatr Hematol Oncol 2009; 26: 216–31. doi: 10.1080/07357900902897557DakkaNBellaouiHBouzidNKhattabMBakriYBenjouadACD10 and CD34 expression in childhood acute lymphoblastic leukemia in morocco: clinical relevance and outcomePediatr Hematol Oncol2009262163110.1080/07357900902897557Open DOISearch in Google Scholar
Cario G, Rhein P, Mitlöhner R, Zimmermann M, Bandapalli OR, Romey R, et al. High CD45 surface expression determines relapse risk in children with precursor B-cell and T-cell acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol. Haematologica 2014; 99: 103–10. doi: 10.3324/haematol.2013.090225CarioGRheinPMitlöhnerRZimmermannMBandapalliORRomeyRHigh CD45 surface expression determines relapse risk in children with precursor B-cell and T-cell acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocolHaematologica2014991031010.3324/haematol.2013.090225Open DOISearch in Google Scholar
Guillaume N, Penther D, Vaida I, Gruson B, Harrivel V, Claisse JF, et al. CD66c expression in B-cell acute lymphoblastic leukemia: strength and weakness. Int J Lab Hematol 2011; 33: 92–6. doi: 10.1111/j.1751-553X.2010.01254.xGuillaumeNPentherDVaidaIGrusonBHarrivelVClaisseJFCD66c expression in B-cell acute lymphoblastic leukemia: strength and weaknessInt J Lab Hematol20113392610.1111/j.1751-553X.2010.01254.xOpen DOISearch in Google Scholar
Kiyokawa N, Iijima K, Tomita O, Miharu M, Hasegawa D, Kobayashi K, et al. Significance of CD66c expression in childhood acute lymphoblastic leukemia. Leuk Res 2014; 38: 2–48. doi: 10.1016/j.leukres.2013.10.008KiyokawaNIijimaKTomitaOMiharuMHasegawaDKobayashiKSignificance of CD66c expression in childhood acute lymphoblastic leukemiaLeuk Res20143824810.1016/j.leukres.2013.10.008Open DOISearch in Google Scholar
Consolini R, Legitimo A, Rondelli R, Guguelmi C, Barisone E, Lippi A, et al. Clinical relevance of CD10 expression in childhood ALL. The Italian Association for Pediatric Hematology and Oncology (AIEOP). Haematologica 1998; 83: 967–73. PMID: 9864914ConsoliniRLegitimoARondelliRGuguelmiCBarisoneELippiAClinical relevance of CD10 expression in childhood ALL. The Italian Association for Pediatric Hematology and Oncology (AIEOP)Haematologica199883967739864914Search in Google Scholar
Mitwasi N, Arndt C, Loureiro LR, Kegler A, Fasslrinner F, Berndt N, et al. Targeting CD10 on B-cell leukemia using the universal CAR T-cell platform (UniCAR). Int J Mol Sci 2022; 23: 4912. doi: 10.3390/ijms23094920MitwasiNArndtCLoureiroLRKeglerAFasslrinnerFBerndtNTargeting CD10 on B-cell leukemia using the universal CAR T-cell platform (UniCAR)Int J Mol Sci202223491210.3390/ijms23094920Open DOISearch in Google Scholar
Gökbuget N, Hoelzer D. Treatment with monoclonal antibodies in acute lymphoblastic leukemia: Current knowledge and future prospects. Ann Hematol 2004; 83: 201–5. doi: 10.1007/s00277-003-0752-8GökbugetNHoelzerDTreatment with monoclonal antibodies in acute lymphoblastic leukemia: Current knowledge and future prospectsAnn Hematol200483201510.1007/s00277-003-0752-8Open DOISearch in Google Scholar
Wang K, Wei G, Liu D. CD19: a biomarker for B cell development, lymphoma diagnosis and therapy. Exp Hematol Oncol 2012; 1: 1–7. doi: 10.1186/2162-3619-1-36WangKWeiGLiuDCD19: a biomarker for B cell development, lymphoma diagnosis and therapyExp Hematol Oncol201211710.1186/2162-3619-1-36Open DOISearch in Google Scholar
Brown PA, Ji L, Xu X, Devidas M, Hogan L, Borowitz JB, et al. A randomized phase 3 trial of blinatumomab vs. chemotherapy as post-reinduction therapy in high and intermediate risk (HR/IR) first relapse of B-acute lymph-oblastic leukemia (B-ALL) in children and adolescents/young adults (AYAs) demonstrates superior efficacy and tolerability of blinatumomab: a report from children’s oncology group study AALL1331. Blood 2019; 134(Suppl 2): LBA-1. doi: 10.1182/blood-2019-132435BrownPAJiLXuXDevidasMHoganLBorowitzJBA randomized phase 3 trial of blinatumomab vs. chemotherapy as post-reinduction therapy in high and intermediate risk (HR/IR) first relapse of B-acute lymph-oblastic leukemia (B-ALL) in children and adolescents/young adults (AYAs) demonstrates superior efficacy and tolerability of blinatumomab: a report from children’s oncology group study AALL1331Blood2019134Suppl 2LBA-110.1182/blood-2019-132435Open DOISearch in Google Scholar
Fabrizio VA, Phillips CL, Lane A, Baggott C, Prabhu S, Egeler E, et al. Tisagenlecleucel outcomes in relapsed/refractory extramedullary ALL: A Pediatric Real World CAR Consortium Report. Blood Adv 2022; 6: 600–10. doi: 10.1182/bloodadvances.2021005564FabrizioVAPhillipsCLLaneABaggottCPrabhuSEgelerETisagenlecleucel outcomes in relapsed/refractory extramedullary ALL: A Pediatric Real World CAR Consortium ReportBlood Adv202266001010.1182/bloodadvances.2021005564Open DOISearch in Google Scholar
Schnitzlein WM, Zuckermann FA. Determination of the specificity of CD45 and CD45R monoclonal antibodies through the use of transfected hamster cells producing individual porcine CD45 isoforms. Vet Immunol Immunopathol 1998; 60: 389–401. doi: 10.1016/S0165-2427(97)00113-XSchnitzleinWMZuckermannFADetermination of the specificity of CD45 and CD45R monoclonal antibodies through the use of transfected hamster cells producing individual porcine CD45 isoformsVet Immunol Immunopathol19986038940110.1016/S0165-2427(97)00113-XOpen DOISearch in Google Scholar
Balasubramanian P, Singh J, Verma D, Kumar R, Bakhshi S, Tanwar P, et al. Prognostic significance of CD45 antigen expression in pediatric acute lymphoblastic leukemia. Blood Cells Mol Dis 2021; 89: 102562. doi: 10.1016/j.bcmd.2021.102562BalasubramanianPSinghJVermaDKumarRBakhshiSTanwarPPrognostic significance of CD45 antigen expression in pediatric acute lymphoblastic leukemiaBlood Cells Mol Dis20218910256210.1016/j.bcmd.2021.102562Open DOISearch in Google Scholar
Zhang Y, Liu Q, Yang S, Liao Q. CD58 Immunobiology at a glance. Front Immunol 2021; 12: 1–20. doi: 10.3389/fimmu.2021.705260ZhangYLiuQYangSLiaoQCD58 Immunobiology at a glanceFront Immunol20211212010.3389/fimmu.2021.705260Open DOISearch in Google Scholar
Zhang X, Voskens CJ, Sallin M, Maniar A, Montes CL, Zhang Y, et al. CD137 promotes proliferation and survival of human B cells. J Immunol 2010; 184: 787–95. doi: 10.4049/jimmunol.0901619ZhangXVoskensCJSallinMManiarAMontesCLZhangYCD137 promotes proliferation and survival of human B cellsJ Immunol20101847879510.4049/jimmunol.0901619Open DOISearch in Google Scholar
Pieters R, Schrappe M, Valsecchi MG, Biondi A, de Rossi G, Suppiah R, et al. International collaborative treatment protocol for the infants under one year with acute lymphoblastic or biphenotypic leukemia - INTERFANT 06. 2008; version 11(17 July 2007). Cochrane Central Register of Controlled Trials. Available at: https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01834165/fullPietersRSchrappeMValsecchiMGBiondiAde RossiGSuppiahRInternational collaborative treatment protocol for the infants under one year with acute lymphoblastic or biphenotypic leukemia - INTERFANT 06. 2008; version 1117July2007Cochrane Central Register of Controlled TrialsAvailable at: https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01834165/fullSearch in Google Scholar
Brozic A, Pohar Marinsek Z, Novakovic S, Kloboves Prevodnik V. Inconclusive flow cytometric surface light chain results; can cytoplasmic light chains, Bcl-2 expression and PCR clonality analysis improve accuracy of cytological diagnoses in B-cell lymphomas? Diagn Pathol 2015; 10: 1–10. doi: 10.1186/s13000-015-0427-5BrozicAPohar MarinsekZNovakovicSKloboves PrevodnikVInconclusive flow cytometric surface light chain results; can cytoplasmic light chains, Bcl-2 expression and PCR clonality analysis improve accuracy of cytological diagnoses in B-cell lymphomas?Diagn Pathol20151011010.1186/s13000-015-0427-5Open DOISearch in Google Scholar
Brožič A. [Clonality and antigenic properties of reactive and neoplastic lymphocytic proliferations]. [Slovenian]. Doctoral Dissertation; 2016. [Internet]. Available at: https://repozitorij.uni-lj.si/IzpisGradiva.php?lang=slv&id=84423BrožičA[Clonality and antigenic properties of reactive and neoplastic lymphocytic proliferations]. [Slovenian]Doctoral Dissertation2016[Internet]. Available at: https://repozitorij.uni-lj.si/IzpisGradiva.php?lang=slv&id=84423Search in Google Scholar
Team RC. A Language and environment for statistical computing. Vienna: R Foundation for Statistical Computin; 2020. [Internet]. [cited 2023 Feb 15]. Available at: cwww.r-project.org/TeamRCA Language and environment for statistical computingViennaR Foundation for Statistical Computin2020[Internet]. [cited 2023 Feb 15]. Available at: cwww.r-project.org/Search in Google Scholar
Bezanson J, Edelman A, Karpinski S, Shah VB. Julia: a fresh approach to numerical computing. SIAM Rev 2017; 59: 65–98. doi: 10.1137/141000671BezansonJEdelmanAKarpinskiSShahVBJulia: a fresh approach to numerical computingSIAM Rev201759659810.1137/141000671Open DOISearch in Google Scholar
Pinheiro J, Bates D, DebRoy S, Sarkar D. Team, R.C. Nlme: Linear and Nonlinear Mixed Effects Models. R Package Version Nov 27 2023. [Internet]. [cited 2023 Dec]. Available at: https://cran.r-project.org/web/packages/nlme/nlme.pdfPinheiroJBatesDDebRoySSarkarDTeam, R.C. Nlme: Linear and Nonlinear Mixed Effects ModelsR Package VersionNov272023[Internet]. [cited 2023 Dec]. Available at: https://cran.r-project.org/web/packages/nlme/nlme.pdfSearch in Google Scholar
Bates D, Alday P, Kleinschmidt D, Calderón JBS, Noack A, Kelman T, et al. JuliaStats/MixedModels.jl: v2.3.0 (v2.3.0). Zenodo; 2020 [Internet]. [cited 2023 Feb 16]. Available at: https://doi.org/10.5281/ZENODO.3727845BatesDAldayPKleinschmidtDCalderónJBSNoackAKelmanTJuliaStats/MixedModels.jl: v2.3.0 (v2.3.0). Zenodo2020[Internet]. [cited 2023 Feb 16]. Available at: https://doi.org/10.5281/ZENODO.3727845Search in Google Scholar
Peterlin J, Kejžar N, Blagus R. Correct specification of design matrices in linear mixed effects models: tests with graphical representation. TEST 2023; 32: 184–210. doi: 10.1007/s11749-022-00830-1PeterlinJKejžarNBlagusRCorrect specification of design matrices in linear mixed effects models: tests with graphical representationTEST20233218421010.1007/s11749-022-00830-1Open DOISearch in Google Scholar
Dworzak MN, Gaipa G, Schumich A, Maglia O, Ratei R, Veltroni M, et al. Modulation of antigen expression in B-cell precursor acute lymphoblastic leukemia during induction therapy is partly transient: evidence for a drug-induced regulatory phenomenon. Results of the AIEOP-BFM-ALL-FLOW-MRD-study group. Cytometry B Clin Cytom 2010; 78: 147–53. doi: 10.1002/cyto.b.20516DworzakMNGaipaGSchumichAMagliaORateiRVeltroniMModulation of antigen expression in B-cell precursor acute lymphoblastic leukemia during induction therapy is partly transient: evidence for a drug-induced regulatory phenomenon. Results of the AIEOP-BFM-ALL-FLOW-MRD-study groupCytometry B Clin Cytom2010781475310.1002/cyto.b.20516Open DOISearch in Google Scholar
Espinoza-Gutarra MR, Agarwal P, Ferrer L, Czader M, Dave U. Relationship between CD45 expression and outcomes in B lymphoblastic leukemia/lymphoma. Blood 2020; 136(Suppl 1): 24. doi: 10.1182/blood-2020-142085Espinoza-GutarraMRAgarwalPFerrerLCzaderMDaveURelationship between CD45 expression and outcomes in B lymphoblastic leukemia/lymphomaBlood2020136Suppl 12410.1182/blood-2020-142085Open DOISearch in Google Scholar
Schwarz H, Valbracht J, Tuckwell J, Von Kempis J, Lotz M. ILA the human 4-1BB homologue, is inducible in lymphoid and other cell lineages. Blood 1995; 85: 1043–52. doi: 10.1182/blood.v85.4.1043.bloodjournal8541043SchwarzHValbrachtJTuckwellJVon KempisJLotzMILA the human 4-1BB homologue, is inducible in lymphoid and other cell lineagesBlood19958510435210.1182/blood.v85.4.1043.bloodjournal8541043Open DOISearch in Google Scholar
Borst J, Hendriks J, Xiao Y. CD27 and CD70 in T cell and B cell activation. Curr Opin Immunol 2005; 17: 275–81. doi: 10.1016/j.coi.2005.04.004BorstJHendriksJXiaoYCD27 and CD70 in T cell and B cell activationCurr Opin Immunol2005172758110.1016/j.coi.2005.04.004Open DOISearch in Google Scholar
Agematsu K, Hokibara S, Nagumo H, Komiyama A. CD27: a memory B-cell marker. Immunol Today 2000; 21: 204–6. doi: 10.1016/S0167-5699(00)01605-4AgematsuKHokibaraSNagumoHKomiyamaACD27: a memory B-cell markerImmunol Today200021204610.1016/S0167-5699(00)01605-4Open DOISearch in Google Scholar
Taraban VY, Rowley TF, Kerr JP, Willoughby JE, Johnson PM, Al-Shamkhani A, et al. CD27 costimulation contributes substantially to the expansion of functional memory CD8+ T cells after peptide immunization. Eur J Immunol 2013; 43: 3314–23. doi: 10.1002/eji.201343579TarabanVYRowleyTFKerrJPWilloughbyJEJohnsonPMAl-ShamkhaniACD27 costimulation contributes substantially to the expansion of functional memory CD8+ T cells after peptide immunizationEur J Immunol20134333142310.1002/eji.201343579Open DOISearch in Google Scholar
Vitale LA, He LZ, Thomas LJ, Widger J, Weidlick J, Crocker A, et al. Development of a human monoclonal antibody for potential therapy of CD27-expressing lymphoma and leukemia. Clin Cancer Res 2012; 18: 3812–21. doi: 10.1158/1078-0432.CCR-11-3308VitaleLAHeLZThomasLJWidgerJWeidlickJCrockerADevelopment of a human monoclonal antibody for potential therapy of CD27-expressing lymphoma and leukemiaClin Cancer Res20121838122110.1158/1078-0432.CCR-11-3308Open DOISearch in Google Scholar
Biondi A, Schrappe M, De Lorenzo P, Castor A, Lucchini G, Gandemer V, Pieters R, et al. Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study. Lancet Oncol 2012; 13: 936–45. doi: 10.1016/S1470-2045(12)70377-7BiondiASchrappeMDe LorenzoPCastorALucchiniGGandemerVPietersRImatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup studyLancet Oncol2012139364510.1016/S1470-2045(12)70377-7Open DOISearch in Google Scholar